Acadia Announces Additions to Executive Team
January 30 2024 - 8:48PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two
new appointments to its executive team. Jennifer J. Rhodes is
joining the company as Executive Vice President, Chief Legal
Officer and Secretary, and Kimberly J. Manhard as Senior Vice
President, Global Strategic Planning and Execution, both effective
immediately. Following a transition period, Austin D. Kim,
Executive Vice President, General Counsel and Secretary will be
leaving Acadia to pursue other opportunities.
“I’m thrilled to announce these two important additions to the
team,” said Steve Davis, Chief Executive Officer. “Jennifer brings
strong executive leadership skills with over 20 years of legal,
strategy and business experience at emerging, rapidly growing and
Fortune 500 life sciences companies. Kimberly’s diverse background
in clinical development, regulatory strategy and commercial product
expansion will be instrumental in advancing our development
pipeline and furthering our efforts to bring DAYBUE to patients
worldwide. We look forward to Jennifer and Kimberly’s contributions
in support of growing our commercial franchises and advancing new
therapies that address significant unmet needs in our patient
communities. I would also like to thank Austin for his leadership
throughout his tenure at Acadia and wish him the best in his future
endeavors.”
Ms. Rhodes most recently served as Executive Vice
President and Chief Business Officer from March 2022 and served as
General Counsel, Chief Compliance Officer and Corporate Secretary
since January 2020 with Angion Biomedica Corp. Ms. Rhodes
previously served as General Counsel and Corporate Secretary at
Adamas Pharmaceuticals, Inc. from April 2016 until January 2020,
during which time she also served as Chief Compliance Officer since
August 2016 and Chief Business Officer since January 2017. Prior to
that, Ms. Rhodes served as General Counsel at Medivation, Inc. from
June 2012 to September 2015, and also served as Corporate Secretary
from April 2013 to September 2015 and as Chief Compliance Officer
from July 2012 to October 2014. From May 2006 to June 2012, Ms.
Rhodes was an Assistant General Counsel at Pfizer Inc., as well as
served as a global product lead for Pfizer Inc.’s primary care
medicines. Earlier in her career, Ms. Rhodes served as an attorney
with the Wall Street firm Weil, Gotshal & Manges LLP. Ms.
Rhodes has a J.D. from Wake Forest University School of Law and a
B.A. in Economics from Newcomb College of Tulane University.
Ms. Manhard most recently served as Executive Vice
President, Drug Development at Heron Therapeutics, Inc. from 2016
to 2023. Previously, Ms. Manhard served as Senior Vice President,
Regulatory Affairs and Development Operations at Ardea Biosciences
Inc. from 2006 to 2016. Earlier in her career, Ms. Manhard served
in various roles of increasing responsibility at Exelixis, Inc.,
Agouron Pharmaceuticals, Inc., Boehringer Ingelheim
Pharmaceuticals, and Bristol Myers Squibb. Ms. Manhard also serves
as a member of the board of directors for Shoreline Biosciences,
Inc., Inhibrx, Inc., and Toragen, Inc. Ms. Manhard obtained a B.S.
in Zoology and B.A. in French from University of Florida,
Gainesville.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on treating the negative symptoms
of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease
psychosis and multiple other programs targeting neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at Acadia.com and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130798452/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com Investor Contact: Acadia
Pharmaceuticals Inc. Al Kildani (858) 261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Jul 2023 to Jul 2024